Largest-ever Ozempic and GLP-1 drug study finds they lower risk of 42 health conditions, including heart attacks and Alzheimer’s disease
The study included nearly 2 million patients, making it the largest ever conducted on this group of glucagon-like peptide-1 ...
GLP-1 drugs linked to lower dementia risk, higher risk of kidney, stomach issues
A new study compares the benefits and risks of taking GLP-1 medications for weight loss, including risks of dementia, ...
GLP-1 weight loss medications pose challenges for c-stores. Here’s how retailers can respond.
Users of Ozempic and other drugs are shunning items like energy drinks and salty snacks, research shows. But there are ...
STAT1d
What can’t GLP-1s do? Study maps benefits while warning of uncommon risks
GLP-1 drugs like Ozempic have swept the world as effective therapies for far more than their original target of diabetes.
24/7 Wall St. on MSN6d
Down 23%, Is This Dividend Giant a Buy After GLP-1 Sales Miss?
Next to artificial intelligence, weight-loss drugs have been one of the biggest themes investors latched onto in 2024. Eli ...
Eli Lilly Stock Tumbles on Slower-Than-Expected Weight Loss Drug Sales. Is This a Buying Opportunity?
Eli Lilly unexpectedly lowered its full-year 2024 guidance. The miss appears to stem from a lack of the typical December ...